Hepatitis C patients' self-reported adherence to treatment with pegylated interferon and ribavirin

被引:30
|
作者
Weiss, J. J. [1 ]
Bhatti, L. [2 ]
Dieterich, D. T. [3 ]
Edlin, B. R. [4 ]
Fishbein, D. A. [3 ]
Goetz, M. B. [5 ,6 ]
Yu, K. [7 ]
Wagner, G. J. [8 ]
机构
[1] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA
[2] AIDS Healthcare Fdn, Los Angeles, CA USA
[3] Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA
[4] Cornell Univ, Weill Med Coll, Ctr Study Hepatitis C, New York, NY 10021 USA
[5] VA Greater Los Angeles Healthcare Syst, Dept Med, Infect Dis Sect, Los Angeles, CA USA
[6] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[7] W LA Kaiser Permanente, Dept Infect Dis, Los Angeles, CA USA
[8] RAND Corp, Hlth Unit, Santa Monica, CA USA
关键词
D O I
10.1111/j.1365-2036.2008.03718.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Prior research on adherence to hepatitis C treatment has documented rates of dose reductions and early treatment discontinuation, but little is known about patients' dose-taking adherence. Aim To assess the prevalence of missed doses of pegylated interferon and ribavirin and examine the correlates of dose-taking adherence in clinic settings. Methods One hundred and eighty patients on treatment for hepatitis C (23% co-infected with HIV) completed a cross-sectional survey at the site of their hepatitis C care. Results Seven per cent of patients reported missing at least one injection of pegylated interferon in the last 4 weeks and 21% reported missing at least one dose of ribavirin in the last 7 days. Dose-taking adherence was not associated with HCV viral load. Conclusions Self-reported dose non-adherence to hepatitis C treatment occurs frequently. Further studies of dose non-adherence (assessed by method other than self-report) and its relationship to HCV virological outcome are warranted.
引用
收藏
页码:289 / 293
页数:5
相关论文
共 50 条
  • [21] Weight loss during pegylated interferon and ribavirin treatment of hepatitis C
    Seyam, M
    Freshwater, DA
    O'Donnell, K
    Mutimer, DJ
    JOURNAL OF HEPATOLOGY, 2004, 40 : 151 - 151
  • [22] Mania during treatment of chronic hepatitis C with pegylated interferon and ribavirin
    Onyike, CU
    Bonner, JO
    Lyketsos, CG
    Treisman, GJ
    AMERICAN JOURNAL OF PSYCHIATRY, 2004, 161 (03): : 429 - 435
  • [23] Lingual hyperpigmentation from pegylated interferon and ribavirin treatment of hepatitis C
    Farshidi, Dina
    Chu, Melvin W.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2010, 62 (01) : 164 - 165
  • [24] POOR ADHERENCE TO TREATMENT WITH PEGYLATED INTERFERON/RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION IS ASSOCIATED WITH GREATER HEALTH CARE COSTS
    Baran, R. W.
    Bhor, M.
    Laitinen, D.
    Dietz, B.
    VALUE IN HEALTH, 2009, 12 (07) : A421 - A421
  • [25] Merimepodib, Pegylated Interferon, and Ribavirin in Genotype 1 Chronic Hepatitis C Pegylated Interferon and Ribavirin Nonresponders
    Rustgi, Vinod K.
    Lee, William M.
    Lawitz, Eric
    Gordon, Stuart C.
    Afdhal, Nezam
    Poordad, Fred
    Bonkovsky, Herbert L.
    Bengtsson, Leif
    Chandorkar, Gurudatt
    Harding, Matthew
    McNair, Lindsay
    Aalyson, Molly
    Alam, John
    Kauffman, Robert
    Gharakhanian, Shahin
    McHutchison, John G.
    HEPATOLOGY, 2009, 50 (06) : 1719 - 1726
  • [26] Dyspnoea in patients with chronic hepatitis C treated with pegylated interferon and ribavirin
    Garib, Junia Rios
    Garcia, Guilherme Freire
    Teixeira, Rosangela
    Lima e Silva, Francisco das Chagas
    SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2011, 43 (08) : 625 - 631
  • [27] Management of depression in patients treated with pegylated interferon and ribavirin for hepatitis C
    Jamil, K. M.
    Cheng, W.
    Tarquinio, L.
    Allet, L.
    Flexman, J.
    Kontorinis, N.
    GUT, 2007, 56 : A126 - A126
  • [28] Using pegylated interferon and ribavirin to treat patients with chronic hepatitis C
    Ward, RP
    Kugelmas, M
    AMERICAN FAMILY PHYSICIAN, 2005, 72 (04) : 655 - 662
  • [29] Management of depression in patients treated with pegylated interferon and ribavirin for hepatitis C
    Jamil, K. M.
    Cheng, W.
    Tarqunio, L.
    Connelly, C.
    McInerney, M.
    Nazareth, S.
    Connelly, C.
    Flexman, J.
    Allet, L.
    Kontorinis, N.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A317 - A317
  • [30] Treatment of chronic hepatitis C with pegylated interferon and ribavirin in treatment-naive patients in 'true life'
    Ridruejo, Ezequiel
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2011, 23 (02) : 195 - 195